Answers are grounded in this paper and cite their sources.
: Our results demonstrate that ZBTB28 functions as a tumor suppressor through competing with BCL6 for targeting p53 regulation. This newly identified ZBTB28/BCL6/p53 regulatory axis provides further molecular insight into carcinogenesis mechanisms and has implications in further improving BCL6-based anticancer therapy.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: